GlassScriptPhysician profile
Michelle Dimza
NPI 1639675549
$12,082.15
in general payments reported to CMS, 2019-2025
14 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $102 · 2021: $2,028 · 2022: $226 · 2023: $2,438 · 2024: $7,092 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $6,750 · Travel and Lodging: $1,586 · Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $6,750.00 |
| Travel and Lodging | $1,585.68 |
| Food and Beverage | $1,391.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,043.59 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Ensite Precision, Cardiomems |
| Biotronik INC. | $1,945.29 | 2021-2022 | |
| Medtronic, INC. | $206.42 | 2021-2022 | |
| Boston Scientific Corporation | $145.09 | 2023 | Watchman Access System |
| Amgen INC. | $122.56 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $121.36 | 2024-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $118.22 | 2020-2025 | Farxiga |
| Abiomed | $115.91 | 2024 | Impella |
| Terumo Medical Corporation | $101.50 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.58 | 2025 | Lifevest |
| Novo Nordisk INC | $44.11 | 2025 | Wegovy |
| Eurofins Viracor, LLC | $36.18 | 2025 | |
| Pfizer INC. | $19.95 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Dimza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.